Interleukin-1: Therapeutic Potential for Solid Tumors

References

• Gery I, Gershon R K, Waksman B H. Potentiation of the T lymphocyte response to mitogens. I. The responding cell. J Exp Med 1972; 136: 128–138
   PubMed Web of Science ®Google Scholar
• Dinarello C A. Interleukin-1. Rev Infect Dis 1984; 6: 51–95
   PubMedGoogle Scholar
• Le J, Vilcek J. Tumor necrosis factor and interleukin 1: Cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234–248
   PubMed Web of Science ®Google Scholar
• Smith K A, Lachman L B, Oppenheim J J, et al. The functional relationship of the interleukins. J Exp Med 1980; 151: 1551–1556
   PubMed Web of Science ®Google Scholar
• Kronheim S R, March C J, Erb S K, et al. Human interleukin 1: Purification to homogeneity. J Exp Med 1985; 161: 490–502
   PubMed Web of Science ®Google Scholar
• Wood D D, Bayne E K, Goldring M B, et al. The four biochemically distinct species of human interleukin 1 all exhibit similar biologic activities. J Immunol 1985; 134: 895–903
   PubMed Web of Science ®Google Scholar
• Webb A C, Collins K L, Auron P E, et al. Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res 1986; 5: 77–85
   PubMedGoogle Scholar
• Modi W S, Masuda A, Yamada M, et al. Chromosomal localization of the human interleukin 1-α (IL-lα) gene. Genomics 1988; 2: 310–314
   PubMed Web of Science ®Google Scholar
• LoMedico P T, Gubler U, Hellmann C P, et al. Cloning and expression of murine interleukin 1 cDNA in Escherichia coli. Nature 1984; 312: 458–462
   PubMed Web of Science ®Google Scholar
• March C J, Mosley B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315: 641–647
   PubMed Web of Science ®Google Scholar
• Gubler U, Chua A O, Stern A S. Recombinant human interleukin 1α: Purification and biological characterization. J Immunol 1986; 136: 2492–2497
   PubMed Web of Science ®Google Scholar
• Gaffney E V, Tsai S C. Lymphocyte-activating and growth-inhibitory activities for several sources of native and recombinant interleukin I. Cancer Res 1986; 46: 3834–3837
   PubMed Web of Science ®Google Scholar
• Conlon P J, Grabstein K H, Prickett K S, et al. Localization of human mononuclear cell interleukin-1. J Immunol 1987; 139: 98–102
   PubMed Web of Science ®Google Scholar
• Kostura M J, Tocci M J, Limjuco G, et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc Natl Acad Sci USA 1989; 86: 5227–5231
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Yamamoto K, Saido T, et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1-α. Proc Natl Acad Sci USA 1990; 87: 5548–5552
   PubMed Web of Science ®Google Scholar
• Matusushima K, Taguchi M, Kovacs F J, et al. Intracellular localization of human monocyte associated interleukin 1 (IL1) activity and release of biologically active IL1 by trypsin and plasmin. J Immunol 1986; 136: 2883–2891
   PubMed Web of Science ®Google Scholar
• Durum S K, Schmidt J A, Oppenheim J, Interleukin J. An immunological perspective. Annu Rev Immunol 1986; 3: 263–287
   Web of Science ®Google Scholar
• Lepe-Zuniga J L, Gery I. Production of intracellular and extracellular interleukin-1 (IL-I) by human monocytes. Clin Immunol Immunopathol 1984; 31: 222–230
   PubMedGoogle Scholar
• Oppenheim J J, Gery I. Interleukin-1 is more than an interleukin. Immunol Today 1982; 3: 113–119
   PubMedGoogle Scholar
• Tiku K, Riku M L, Skosey J L. Interleukin-1 production by human polymorphonuclear neutrophils. J Immunol 1986; 136: 3677–3685
   PubMed Web of Science ®Google Scholar
• Acres B R, Larsen A, Conlon P F. IL-I expression in a clone of human T-cells. J Immunol 1987; 138: 2132–2136
   PubMed Web of Science ®Google Scholar
• Scala G, Allaveena P, Djeu J, et al. Human large granular lymphocytes are potent producers of interleukin-1. Nature 1984; 309: 56–59
   PubMed Web of Science ®Google Scholar
• Pistoia V, Cozzolino F, Rubartelli A, et al. In vitro production of interleukin-1 by normal and malignant human B-lymphocytes. J Immunol 1986; 136: 1688–1692
   PubMed Web of Science ®Google Scholar
• Giulian D, Lachman L B. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 1985; 22: 497–499
   Google Scholar
• Akahoshi T, Oppenheim J J, Matsushima K. Interleukin-1 stimulates its own receptor expression on human fibroblasts through the endogenous production of prostaglandin(s). J Clin Invest 1988; 82: 1219–1224
   PubMed Web of Science ®Google Scholar
• Sauder D N. Epidermal-derived cytokines: Properties of epidermal-derived thymocyte activating factor. Lymphokine Res 1985; 3: 145–151
   Google Scholar
• Libby R, Ordovas J M, Auger K R, et al. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 1986; 124: 179–186
   PubMed Web of Science ®Google Scholar
• Libby R, Ordovas J M, Auger K R, et al. Inducible interleukin-1 gene expression in vascular smooth muscle cells. J Clin Invest 1986; 78: 1432–1438
   PubMed Web of Science ®Google Scholar
• Koyama N, Harada N, Takahashi T, et al. Role of recombinant interleukin-1 compared to recombinant T-cell replacing factor/interleukin-5 in B-cell differentiation. Immunol 1988; 63: 277–283
   PubMed Web of Science ®Google Scholar
• Fontana A, Grob P J. Astrocyte-derived interleukin-1 like factors. Lymphokine Res 1984; 3: 11–16
   PubMedGoogle Scholar
• Oppenheim J J, Kovacs E J, Matsushima, et al. There is more than one interleukin 1. Immunol Today 1986; 7: 45–56
   PubMedGoogle Scholar
• Dower S K, Kronheim S R, March C J, et al. Detection and characterization of high-affinity plasma membrane receptors for human interleukin 1. J Exp Med 1985; 162: 501–515
   PubMed Web of Science ®Google Scholar
• Chizzonite R, Truitt T, Kilian P L, et al. Two high-affinity interleukin-1 receptors represent separate gene products. Proc Natl Acad Sci USA 1989; 86: 8029–8033
   PubMed Web of Science ®Google Scholar
• Horuk R, Huang J J, Covington M, et al. A biochemical and kinetic analysis of the interleukin-1 receptor. Evidence for differences in molecular properties of IL-1 receptors. J Biol Chem 1987; 262: 16275–16278
   PubMed Web of Science ®Google Scholar
• Mizuno K, Nakai S, Ohmoto Y, et al. Identification of a specific receptor for IL-1 on rat bone marrow cells. FEBS Lett 1989; 257: 27–30
   PubMed Web of Science ®Google Scholar
• Uhl J, Newton R C, Giri J G, et al. Identification of IL-1 receptors on human monocytes. J Immunol 1989; 142: 1576–1581
   PubMed Web of Science ®Google Scholar
• Rhyne J A, Mizel S B, Taylor R G, et al. Characterization of the human interleukin-1 receptor on human polymorphonuclear leukocytes. Clin Immunol Immunopathol 1988; 48: 354–361
   PubMedGoogle Scholar
• Sims J E, Acres B, Grubin C E, et al. Cloning the interleukin 1 receptor from human T cells. Proc Natl Acad Sci USA 1989; 86: 8946–8950
   PubMed Web of Science ®Google Scholar
• McMahan C J, Slack J L, Mosley B, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 1991; 10: 2821–2832
   PubMed Web of Science ®Google Scholar
• Kilian P L, Kaffka K L, Stern A S, et al. Interleukin 1α and interleukin 1β bind to the same receptor on T cells. J Immunol 1986; 136: 4509–4514
   PubMed Web of Science ®Google Scholar
• Chin J, Cameron P M, Rupp E, et al. Identification of a high-affinity receptor for native human interleukin 1β and interleukin 1α on normal human lung fibroblasts. J Exp Med 1987; 165: 70–86
   PubMed Web of Science ®Google Scholar
• Clark B D, Ikejima T, Mancilla J, . An antibody to a 17 amino acid synthetic peptide of the 80 kDa IL-IR blocks IL-I binding to this receptor. Molecular and Cellular Biology of Cytokines, J J Oppenheim, M C Powanda, M J Kluger, C A Dinarello, et al. Wiley-Liss, New York 1990; 131–136
   Google Scholar
• Ikejima T, Clark B D, Mancilla J, et al. Affinity purified antibodies against a 17 amino acid portion of murine IL-IR recognizes 80 kDa (lL-1Rtl) peptide and blocks differentially IL-lα and IL-1β binding on D10S cells. Lymph Res 1990; 9: 583
   Google Scholar
• Larrick J W. Native interleukin I inhibitors. Immunol Today 1989; 10: 61–66
   PubMedGoogle Scholar
• Arend W P, Joslin F G, Thompson R C, et al. An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J Immunol 1989; 143: 1851–1858
   PubMed Web of Science ®Google Scholar
• Hannum C H, Wilcox C J, Arend W P, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336–340
   PubMed Web of Science ®Google Scholar
• Eisenberg S P, Evans R J, Arend W P, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341–346
   PubMed Web of Science ®Google Scholar
• Carter D B, Deibel M R, Dunn C J, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990; 344: 633–638
   PubMed Web of Science ®Google Scholar
• Dinarello C A. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–1652
   PubMed Web of Science ®Google Scholar
• McIntyre K W, Stepan G J, Kolinsky K D, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173: 931–939
   PubMed Web of Science ®Google Scholar
• Ulich T R, Yin S, Guo K, et al. The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. Am J Pathol 1991; 138: 521–524
   PubMed Web of Science ®Google Scholar
• Wakabayashi G, Gelfand J A, Burke J F, et al. A specific receptor antagonist for interleukin 1 prevents Escherichia coli- induced shock in rabbits. FASEB J 1991; 5: 338–343
   PubMed Web of Science ®Google Scholar
• Alexander H R, Doherty G M, Buresh C M, et al. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173: 1029–1032
   PubMed Web of Science ®Google Scholar
• Dripps D J, Brandhuber B J, Thompson R C, et al. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331–10336
   PubMed Web of Science ®Google Scholar
• Larsson E L, Iscove N N, Coutinho A. Two distinct factors are required for induction of T-cell growth. Nature 1980; 283: 664–666
   PubMed Web of Science ®Google Scholar
• Smith K A. Interleukin-2. Annu Rev Immunol 1984; 2: 319–333
   PubMed Web of Science ®Google Scholar
• Herrmann F, Oster W, Meuer S C, et al. Interleukin-1 induces T-cell production of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1988; 81: 1415–1418
   PubMed Web of Science ®Google Scholar
• Abbas A K. Cellular interactions in the immune response. The role of B-lymphocytes and interleukin-4. Am J Pathol 1987; 129: 26–33
   Web of Science ®Google Scholar
• Helle M, Boeije L, Aarden L A. IL-6 is an intermediate in IL-1 induced thymocyte proliferation. J Immunol 1989; 142: 4335–4338
   PubMed Web of Science ®Google Scholar
• Reem G H, Yeh N H. Interleukin-2 regulates expression of its receptor and synthesis of gamma interferon by human T-lymphocytes. Science 1984; 225: 429–430
   PubMed Web of Science ®Google Scholar
• Herrmann F, Mertelsmann R. Polypeptides controlling hematopoietic cell development and activation. I. In vitro results. Blut 1989; 58: 117–128
   PubMedGoogle Scholar
• Wood D D, Cameron P M. Stimulation of the release of a B-cell-activating factor from human monocytes. Cell Immunol 1976; 21: 133–145
   PubMed Web of Science ®Google Scholar
• Falkoff R JM, Muraguchi A, Hong J X, et al. The effects of interleukin-1 on human B-cell activation and proliferation. J Immunol 1983; 131: 801–805
   PubMed Web of Science ®Google Scholar
• Lipsky P E, Thompson P A, Rosenwasser L J, et al. The role of interleukin-1 in human B-cell activation: Inhibition of B-cell proliferation and the generation of immunoglobulin secreting cells by an antibody against human leukocytic pyrogen. J Immunol 1983; 130: 2709–2714
   Google Scholar
• Kurt-Jones E A, Beller D I, Mizel S B, et al. Identification of a membrane-associated interleukin-1 in macrophages. Proc Natl Acad Sci USA 1985; 82: 1204–1208
   PubMed Web of Science ®Google Scholar
• Bonnefoy J-Y, Denoroy M-C, Guillot O, et al. Activation of normal human B-cells through their antigen receptor induces membrane expression of IL-α and secretion of IL-1β. J Immunol 1989; 143: 864–869
   PubMed Web of Science ®Google Scholar
• Tosato G, Seamon K B, Goldman N D, et al. Monocyte derived human B-cell growth factor identified as interferon-beta2 (BSF-2, IL-6). Science 1988; 239: 502–505
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1–10
   PubMed Web of Science ®Google Scholar
• Philip R, Epstein L B. Tumor necrosis factor as immunomodula-tor and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1986; 323: 86–89
   PubMed Web of Science ®Google Scholar
• Onozaki K, Matsushima K, Kleinerman E S, et al. Role of interleukin-1 (IL-1) in promoting human mediated tumor cytotoxicity. J Immunol 1985; 135: 314–320
   PubMed Web of Science ®Google Scholar
• Lovett D, Kozan B, Hadam M, et al. Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol 1986; 136: 340–347
   PubMed Web of Science ®Google Scholar
• Dempsey R A, Dinarello C A, Mier J W, et al. The differential effects of human leukocytic pyrogen/lymphocyte activating factor. T-cell growth factor and interferon on human natural killer cell activity. J Immunol 1982; 129: 2504–2510
   PubMed Web of Science ®Google Scholar
• Aribia M B, Leroy E, Lantz O, et al. Recombinant IL-2 induced proliferation of human circulating NK cells and T-lymphocytes: Synergistic effects of IL-1 and IL-2. J Immunol 1987; 139: 443–451
   PubMed Web of Science ®Google Scholar
• Crump W L, III, Owen-Schaub L B, Grimm E A. Synergy of human recombinant interleukin-1 with interleukin-2 in the generation of lymphokine activated killer cells. Cancer Res 1989; 49: 149–153
   PubMed Web of Science ®Google Scholar
• Herman J, Kew M C, Rabson A R. Defective interleukin-1 production by natural killer cells of patients with cancer. Cancer Immunol Immunother 1985; 19: 148–153
   PubMed Web of Science ®Google Scholar
• Garraud O, Faucher A, Legrand E. Impairment of monocyte functions in advanced head and neck cancer. Immunol Lett 1988; 18: 213–218
   PubMed Web of Science ®Google Scholar
• Johnson C S, Keckler D J, Topper M I, et al. In vivo hematopoietic effects of recombinant interleukin-1α in mice: Stimulation of granulocytic, monocytic, megakaryocyte, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678–683
   PubMed Web of Science ®Google Scholar
• Stork L C, Peterson U M, Rundus C H, et al. Interleukin-1 enhances murine granulopoiesis in vivo. Exp Hematol 1988; 16: 163–167
   PubMed Web of Science ®Google Scholar
• Moore M AS, Warren D J. Synergy of interleukin-1 and granulocyte colony-stimulating factor: In vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluoroura-cil treatment of mice. Proc Natl Acad Sci USA 1987; 84: 7134–7138
   PubMed Web of Science ®Google Scholar
• Mochizuki D Y, Eisenman J R, Conlon P G, et al. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc Natl Acad Sci USA 1987; 84: 5267–5271
   PubMed Web of Science ®Google Scholar
• Zucali J R, Broxmeyer H E, Dinarello C A, et al. Regulation of early human hematopoietic (BFU-E and CFU-GEMM) progenitor cells in vitro by interleukin-1-induced fibroblast-conditioned medium. Blood 1987; 69: 33–37
   PubMed Web of Science ®Google Scholar
• Jubinsky P T, Stanley E R. Purification of hemopoietin 1: A multilineage hemopoietic growth factor. Proc Natl Acad Sci USA 1985; 82: 2764–2768
   PubMed Web of Science ®Google Scholar
• Bagby G C, Jr. Interleukin-1 and hematopoiesis. Blood Rev 1989; 3: 152–161
   PubMed Web of Science ®Google Scholar
• Fibbe W E, Falkenburg J HF, Schaafsma M R, et al. The hematopoietic activities of interleukin 1. Biotherapy 1989; 1: 263–271
   PubMedGoogle Scholar
• Williams D E, Broxmeyer H E. Interleukin-1α enhances the in vitro survival of purified murine granulocyte-macrophage progenitor cells in the absence of colony-stimulating factors. Blood 1988; 72: 1608–1615
   PubMed Web of Science ®Google Scholar
• Hangoc G, Williams D E, Falkenburg J HF, et al. Influence of IL-1α and IL-1β on the survival of human bone marrow cells responding to hematopoietic colony-stimulating factors. J Immunol 1989; 142: 4329–4334
   PubMed Web of Science ®Google Scholar
• Ulich T R, delCastillo J, Keys M, et al. Kinetics and mechanisms of recombinant human interleukin-1 and tumor necrosis factor induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987; 139: 3406–3415
   PubMed Web of Science ®Google Scholar
• Van Damme J, Opdenakker G, DeLey M, et al. Pyrogenic and hematological effects of the interferon-inducing 22K factor (interleukin-1) from human leukocytes. Clin Exp Immunol 1986; 66: 303–311
   PubMed Web of Science ®Google Scholar
• Bradley T R, Williams N, Kriegler A B, et al. In vivo effects of interleukin-1α on regenerating mouse bone marrow myeloid colony forming cells after treatment with 5-fluorouracil. Leukemia 1989; 3: 893–896
   PubMed Web of Science ®Google Scholar
• Neta R, Douches S, Oppenheim J J. Interleukin-1 is a radioprotector. J Immunol 1986; 136: 2483–2485
   PubMed Web of Science ®Google Scholar
• Neta R, Sztein M B, Oppenheim, et al. The in vivo effects of interleukin-1. I. Bone marrow cells are induced by cycle after administration of interleukin-1. J Immunol 1987; 139: 1861–1866
   PubMed Web of Science ®Google Scholar
• Neta R, Oppenheim J J, Douches S D. Interdependence of the radioprotective effects of human recombinant interleukin-1, tumor necrosis factor, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor. J Immunol 1988; 140: 108–111
   PubMed Web of Science ®Google Scholar
• Oppenheim J J, Neta R, Tiberghien P, et al. Interleukin-1 enhances survival of lethally irradiated mice treated with allogeneic bone marrow cells. Blood 1989; 74: 2257–2263
   PubMed Web of Science ®Google Scholar
• Stork L, Barczuk L, Kissinger M, et al. Interleukin-1 accelerates murine granulocyte recovery following treatment with cyclophosphamide. Blood 1989; 73: 938–944
   PubMed Web of Science ®Google Scholar
• Moore M AS, Stolfi R L, Martin D S, et al. Hematologic effects of interleukin-1 beta, granulocyte-macrophage colony-stimulating factor in tumor-bearing mice treated with fluorouracil. J Natl Cancer Inst 1990; 82: 1031–1037
   PubMed Web of Science ®Google Scholar
• Gasparetto C, Laver J, Abbound M, et al. Effects of interleukin-1 on hematopoietic progenitors: Evidence of stimulatory and inhibitory activities in a primate model. Blood 1989; 74: 547–550
   PubMed Web of Science ®Google Scholar
• Zucali J R, Moreb J, Bain C. Protection of cells capable of reconstituting long-term bone marrow stromal cultures from 4-hydroperoxycyclophosphamide by interleukin 1 and tumor necrosis factor. Exp Hematol 1992; 20: 969–973
   PubMed Web of Science ®Google Scholar
• Damia G, Komschlies K L, Futami H, et al. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: Protection from hematological and nonhematological toxicities. Cancer Res 1992; 52: 4082–4089
   PubMed Web of Science ®Google Scholar
• Williams D E, Morrissey P J. Alterations in megakaryocyte and platelet compartments following in vivo IL-1 beta administration to normal mice. J Immunol 1989; 142: 4361–4365
   PubMed Web of Science ®Google Scholar
• Tewari A, Buhles W C, Jr, Starnes H F, Jr, et al. Preliminary report: Effects of interleukin-1 on platelet counts. Lancet 1990; 336: 712–714
   PubMed Web of Science ®Google Scholar
• Johnson C S, Pourbohloul S C, Furmanski P. Negative regulators of in vivo erythropoiesis: Interaction of IL-1α and TNF-α and the lack of a strict requirement for T or NK cells for their activity. Exp Hematol 1991; 19: 101–105
   PubMed Web of Science ®Google Scholar
• Johnson C S, Chang M J, Furmanski P. In vivo hematopoietic effects of tumor necrosis factor-a in normal and erythroleukemic mice: Characterization and therapeutic applications. Blood 1988; 72: 1875–1883
   PubMed Web of Science ®Google Scholar
• Chang M J, Pourbohloul S C, Yu W D, et al. Differential effect in vitro of tumor necrosis factor-α (TNF) on normal and virus-infected erythroid progenitors from Friend virus (FVA) infected mice. Exp Hematol 1992; 20: 881–887
   Google Scholar
• Johnson C S, Cook C A, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-α (TNF-α): Reversal with exogenous erythropoietin (EPO). Exp Hematol 1990; 18: 109–113
   PubMed Web of Science ®Google Scholar
• Dinarello C A. Interleukin 1. Its multiple biological effects and its association with hemodialysis. Blood Purif 1988; 6: 164–172
   PubMed Web of Science ®Google Scholar
• Dejana E, Brenario F, Erroi A, et al. Modulation of endothelial cell function by difference molecular species of interleukin-1. Blood 1987; 69: 635–699
   Google Scholar
• Okusawa S, Gelfand J A, Ikejima T, et al. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162–1172
   PubMed Web of Science ®Google Scholar
• Smith J, Urba W, Steis R, et al. Interleukin-1α: Results of a phase I toxicity and immunomodulatory trial. Am Soc Clin Oncol 1990; 9: 717
   Google Scholar
• Beasley D S, Cohen R A, Levinsky N G. Interleukin-1 inhibits contraction of vascular smooth muscle. J Clin Invest 1989; 83: 331–335
   PubMed Web of Science ®Google Scholar
• Beasley D, Schwartz J H, Brenner B M. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991; 87: 602–608
   PubMed Web of Science ®Google Scholar
• Bevilacqua M P, Pober J S, Majeau G R, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533–4537
   PubMed Web of Science ®Google Scholar
• Rossi V, Breviario F, Ghezzi P, et al. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229: 174–176
   PubMed Web of Science ®Google Scholar
• Nachman R L, Hajjar K A, Silverstein R L, et al. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595–1600
   PubMed Web of Science ®Google Scholar
• Emeis J J, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260–1266
   PubMed Web of Science ®Google Scholar
• Pober J S, Gimbrone M A, Jr, Lapierre L A, et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 1986; 137: 1893–1896
   PubMed Web of Science ®Google Scholar
• Nawroth P P, Bank I, Handley D, et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1363–1375
   PubMed Web of Science ®Google Scholar
• Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740–745
   PubMed Web of Science ®Google Scholar
• vanHinsbergh V WM, vanden Berg E A, Fiers W, et al. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991–1998
   PubMed Web of Science ®Google Scholar
• Pohlman T H, Stanness K A, Beatty P G, et al. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol 1986; 136: 4548–4553
   PubMed Web of Science ®Google Scholar
• Lamas A M, Mulroney C M, Schleimer R P. Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. J Immunol 1988; 140: 1500–1505
   PubMed Web of Science ®Google Scholar
• Onozaki K, Matsushima K, Aggarwal B B, et al. Interleukin-1 as a cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 3962–3968
   PubMed Web of Science ®Google Scholar
• Lachman L B, Dinarello C A, Llanska N D, et al. Natural and recombinant human interleukin- 1β is cytotoxic for human melanoma cells. J Immunol 1986; 136: 3098–3103
   PubMed Web of Science ®Google Scholar
• Gaffney E V, Tsai S C. Lymphocyte activating and growth inhibiting activities for several sources of native and recombinant interleukin-1. Cancer Res 1986; 46: 3834–3837
   PubMed Web of Science ®Google Scholar
• Kilian P L, Kaffka K L, Biondi D A, et al. Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH: OVCAR-3). Cancer Res 1991; 51: 1823–1828
   PubMed Web of Science ®Google Scholar
• Braunschweiger P G, Johnson C S, Kumar N, et al. Antitumor effects of recombinant human interleukin-1α in RIF-1 and Panc02 solid tumors. Cancer Res 1988; 48: 6011–6016
   PubMed Web of Science ®Google Scholar
• Nakamura S, Nakata K, Kashimoto S, et al. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors. Jpn J Cancer Res 1986; 77: 767–773
   PubMedGoogle Scholar
• Pezzella M, Neville M E, Huang J J. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin-1β. I. Tumor inhibition parallels lymphocyte activating factor activity of interleukin-1β proteins. Cytokine 1990; 2: 357–362
   PubMedGoogle Scholar
• Neville M E, Pezzella K M, Schmidt K, et al. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin-1β. II. Mechanism of inhibition: The role of polymorphonuclear leukocytes. Cytokine 1990; 2: 456–463
   PubMedGoogle Scholar
• North R J, Neubauer R H, Huang J JH, et al. Interleukin 1-in-duced, T cell-mediated regression of immunogenic murine tumors. J Exp Med 1988; 168: 2031–2043
   PubMed Web of Science ®Google Scholar
• Naka K, Kashimoto S, Yoshida H, et al. Augmented antitumor effect of recombinant human interleukin-1α by indomethacin. Cancer Res 1988; 48: 584–588
   PubMed Web of Science ®Google Scholar
• Carswell E A, Old L J, Kassel R L, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–3670
   PubMed Web of Science ®Google Scholar
• Old L J. Tumor necrosis factor (TNF). Science 1985; 230: 630–632
   PubMed Web of Science ®Google Scholar
• Tracey K J, Beutley B, Lowry S F, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1987; 234: 470–474
   Web of Science ®Google Scholar
• Nawroth P, Handley D, Matsueda G, et al. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988; 168: 637–647
   PubMed Web of Science ®Google Scholar
• Kallinowski F, Schaefer C, Tyler G, et al. In vivo targets of recombinant human tumour necrosis factor-α: Blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer 1989; 60: 555–560
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989; 81: 497–502
   PubMed Web of Science ®Google Scholar
• Belardelli F, Proietti E, Ciolli J, et al. Interleukin-1β induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the antitumor effects of tumor necrosis factor α and β. Int J Cancer 1989; 44: 116–123
   PubMed Web of Science ®Google Scholar
• Constantinidis I, Braunschweiger P G, Wehrle J P, et al. 31P-nuclear magnetic resonance studies of the effect of recombinant human interleukin-1α on the bioenergetics of RIF-1 tumors. Cancer Res 1989; 49: 6379–6382
   PubMed Web of Science ®Google Scholar
• Braunschweiger P G, Kumar N, Constantinidis I, et al. Potentiation of interleukin-1α mediated antitumor effects by ketoconazole. Cancer Res 1990; 50: 4709–4717
   PubMed Web of Science ®Google Scholar
• Johnson C S, Chang M, Braunschweiger P G, et al. Acute hemorrhagic necrosis of tumors induced by interleukin-1α: Effects independent of tumor necrosis factor. J Natl Cancer Inst 1991; 83: 842–848
   PubMed Web of Science ®Google Scholar
• Braunschweiger P G, Johnson C S, Kumar N, et al. The effect of adrenalectomy and dexamethasone on interleukin-1α induced responses in RIF-1 tumours. Br J Cancer 1990; 61: 9–13
   PubMed Web of Science ®Google Scholar
• North R J, Havell E A. The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J Exp Med 1988; 167: 1086–1099
   PubMed Web of Science ®Google Scholar
• Havell E A, Fiers W, North R J. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 1988; 167: 1067–1085
   PubMed Web of Science ®Google Scholar
• Usui N, Mimnaugh E G, Sinha B K. Synergistic antitumor activity of etoposide and human interleukin-1α against human melanoma cells. J Natl Cancer Inst 1989; 81: 1904–1909
   PubMed Web of Science ®Google Scholar
• Usui N, Mimnaugh, Sinha B K. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1α and etoposide against human melanoma cells. Cancer Res 1991; 51: 769–774
   PubMed Web of Science ®Google Scholar
• Nakamura S, Kashimoto S, Kajikawa F, et al. Combination effect of recombinant human interleukin-1α with antitumor drugs on syngeneic tumors in mice. Cancer Res 1991; 51: 215–221
   PubMed Web of Science ®Google Scholar
• Braunschweiger P G, Jones S A, Johnson C S, et al. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin-1α. Cancer Res 1991; 51: 5454–5460
   PubMed Web of Science ®Google Scholar
• Chang M J, Yu W D, Modzelewski R A, et al. Interleukin-la enhancement of in vivo cisplatin mediated antitumor activities. Proc Am Assoc Cancer Res 1992; 33: 443
   Google Scholar
• Yu W D, Chang M J, Modzelewski R A, et al. Synergistic interaction of IL-1α and cisplatin for clonogenic tumor cell kill determined by median dose-effect analysis. Proc Am Assoc Cancer Res 1992; 33: 505
   Google Scholar
• Bani M R, Garofalo A, Scanziani E, et al. Effect of interleukin-1-beta on metastasis formation in different tumor systems. J Natl Cancer Inst 1991; 83: 119–123
   PubMed Web of Science ®Google Scholar
• Castelli M P, Black P L, Schneider M, et al. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J Immunol 1988; 140: 3830–3837
   PubMed Web of Science ®Google Scholar
• Smith J W, Urba W J, Curti B D, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10: 1141–1152
   PubMed Web of Science ®Google Scholar
• Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78: 1420–1427
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Kudelka A, Garrison L, et al. Interleukin-1α (IL-1α) increases circulating platelet (PLT) counts and reduces carboplatin (CBDCA)-induced thrombocytopenia. Proc Am Soc Clin Oncol 1992; 11: 224
   Google Scholar
• Smith J, Longo D, Alvord W, et al. Thrombopoietic effects of IL-la in combination with high-dose carboplatin. Proc Am Soc Clin Oncol 1992; 11: 252
   Google Scholar
• Dennis D, Chachoua A, Caron D, et al. Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies. Proc Am Soc Clin Oncol 1992; 11: 255
   Google Scholar
• Puri R K, Travis W D, Rosenberg S A. Decrease in interleukin-2 induced vascular leakage in the lungs of mice by administration of recombinant interleukin-1 alpha in vivo. Cancer Res 1989; 49: 969–976
   PubMed Web of Science ®Google Scholar
• Rosenstein M, Ettinghausen S E, Rosenberg S A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986; 137: 1735–1742
   PubMed Web of Science ®Google Scholar
• McCune C S, Marquis D M. Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 1990; 50: 1212–1215
   Google Scholar
• Sorenson C M, Barry M A, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749–755
   PubMed Web of Science ®Google Scholar